Mechelen, Belgium;
12 August 2008 – Galapagos NV (Euronext: GLPG) announced
today that its service division BioFocus DPI and UCB have
signed a contract for the provision of chemistry services
in the UK by BioFocus DPI, for one of UCB’s medicinal
chemistry programs. The total contract value for Galapagos
could potentially exceed €4 M. Additionally, Galapagos
is eligible to receive up to €500,000 in success payments
subject to fulfillment of certain conditions.
UCB will transfer a team
of chemists to BioFocus DPI from UCB’s recently closed
Cambridge (UK) research site and BioFocus DPI will continue
the chemistry work for the program that was running at UCB,
towards candidate selection stage. Under the contract, UCB
will provide biology support for the program.
“This agreement with
UCB demonstrates BioFocus DPI’s flexibility in meeting
client needs,” said Chris Newton, Senior Vice President
of BioFocus DPI. “This innovative deal structure allows
UCB to progress their program externally while applying
the specific project expertise that UCB has already built
internally.”
“UCB is delighted
to be able to work with BioFocus DPI in this way, combining
our expertise to advance this programme towards development,”
said Dr Neil Weir, Senior Vice President Research, UCB.
About Galapagos and BioFocus DPI
Galapagos (Euronext Brussels: GLPG; Euronext Amsterdam:
GLPGA; OTC: GLPYY) is a drug discovery company with pre-clinical
programs in bone and joint diseases and bone metastasis.
Its division BioFocus DPI offers a full suite of target-to-drug
discovery products and services to pharmaceutical and biotech
companies, encompassing target discovery and validation,
screening and drug discovery through to delivery of pre-clinical
candidates. BioFocus DPI also provides adenoviral reagents
for rapid identification and validation of novel drug targets,
compound libraries for drug screening as well as ADMET products
to select compounds. Galapagos currently employs 490 people
and operates facilities in six countries, with global headquarters
in Mechelen, Belgium. More information about Galapagos and
BioFocus DPI can be found at www.glpg.com
and www.biofocusdpi.com.
CONTACTS
Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir@glpg.com
This release may contain forward-looking statements,
including, without limitation, statements containing the
words “believes,” “anticipates,”
“expects,” “intends,” “plans,”
“seeks,” “estimates,” “may,”
“will,” “could,” “stands to,”
and “continues,” as well as similar expressions.
Such forward-looking statements may involve known and unknown
risks, uncertainties and other factors which might cause
the actual results, financial condition, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial
conditions, performance or achievements expressed or implied
by such forward-looking statements. Given these uncertainties,
the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements
speak only as of the date of publication of this document.
Galapagos expressly disclaims any obligation to update any
such forward-looking statements in this document to reflect
any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any
such statement is based, unless required by law or regulation.
